Yes to both questions. BAX/MNTA’s intention is to run a single phase-3 trial for registration of M923 (Humira FoB) in multiple jurisdictions, including the U.S.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”